Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Last trade$7.48
Day change-$0.22 (-2.86%)
Day range$7.43 – $8.16
Volume1,837,626
Market cap$970M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$970.31M
Price / earnings
—
Price / book
96.06×
Price / sales
9.67×
EV / sales
9.21×
EV / EBITDA
-4.79×
Profitability
Earnings per share
-$1.42
Return on assets
-77.91%
Return on equity
-1,771.14%
Dividend yield
0%
Liquidity and leverage
Debt / equity
12.46×
Current ratio
1.93×
Quick ratio
1.91×
Cash ratio
1.67×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$159.57M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VSTM, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$24.01M
$40.08M
$18.67M
$17.54M
$11.24M
$2.14M
$0
$0
Cost of revenue
$3.95M
$4.04M
$3.05M
$2.61M
$1.96M
$446K
$0
$0
Gross profit
$20.07M
$36.04M
$15.62M
$14.92M
$9.28M
$1.69M
$0
$0
Selling, general and administrative
$26.49M
$27.41M
$22.3M
$24.44M
$21.01M
$20.67M
$15.02M
$10.78M
Research and development
$68.81M
$41.34M
$38.22M
$31.67M
$28.99M
$24.79M
$29.15M
$20.81M
Total operating expenses
$95.29M
$68.75M
$60.52M
$56.4M
$50M
$45.46M
$44.17M
$31.59M
Operating income
-$75.22M
-$32.71M
-$44.9M
-$41.48M
-$40.72M
-$43.76M
-$44.17M
-$31.59M
Interest expense
-$212K
-$360K
-$382K
-$415K
-$319K
-$212K
-$192K
-$1.15M
Income before taxes
-$74.72M
-$33.86M
-$36.59M
-$32.92M
-$98.52M
-$25.93M
-$52.1M
-$64.37M
Income taxes
$0
$816K
$0
$0
$0
$0
$0
$185K
Net income
-$74.72M
-$34.67M
-$36.59M
-$32.92M
-$98.52M
-$25.93M
-$52.1M
-$64.55M
Net income attributable to common shareholders
-$74.72M
-$34.67M
-$36.59M
-$32.92M
-$98.52M
-$25.93M
-$52.1M
-$64.55M
EBITDA
-$74.95M
-$32.43M
-$44.62M
-$40.76M
-$40.42M
-$43.64M
-$44.16M
-$31.58M
Basic earnings per share
-$0.74
-$0.35
-$0.37
-$0.39
-$1.35
-$0.39
-$0.96
-$1.32
Diluted earnings per share
-$0.74
-$0.35
-$0.46
-$0.43
-$1.35
-$0.62
-$0.96
-$1.32
Recent news
Company coverage with links to the original publishers.
Clene Inc. (CLNN) reported quarterly earnings of $0.05 per share, beating consensus estimates of a $0.46 loss, representing a +110.87% earnings surprise. However, the company missed revenue expectations with $0.06 million versus the consensus estimate, down 37.78%. The stock has underperformed the market by 35.8% year-to-date and carries a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
The colorectal cancer market is projected to grow significantly from 2026-2036, driven by rising incidence rates, increased disease awareness, and adoption of targeted therapies and immunotherapies. The market was valued at approximately USD 13 billion in 2025. Key growth drivers include emerging therapies targeting KRAS G12C, NTRK fusions, and PIK3CA mutations, with major pharmaceutical companies launching innovative treatments. The US accounts for the largest market share among the 7 major markets analyzed.
Verastem (VSTM) closed at $8.38 with a mean analyst price target of $15, suggesting 79% upside potential. The stock has gained 14.5% over the past four weeks. Analysts have revised earnings estimates higher, and VSTM holds a Zacks Rank #2 (Buy) rating. However, the article cautions that price targets should not be the sole basis for investment decisions, as they are often overly optimistic.
Genmab shares rallied 10.7% following positive phase III trial data for epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymphoma. The stock's consensus EPS estimate was revised 8.7% higher over the past 30 days, though earnings are expected to decline 43.1% year-over-year while revenues grow 15.7%. The stock carries a Zacks Rank #3 (Hold) rating.
Verastem (VSTM) shares have surged 121% over three months, driven by accelerating sales of ovarian cancer drug Avmapki Fakzynja Co-Pack, which generated $25.1 million in Q2 2026 revenues (up 1,095% YoY), and growing optimism around VS-7375, a KRAS G12D inhibitor in phase II trials across pancreatic, lung, and colorectal cancers. The company expects VS-7375 data in October 2026 and plans FDA meetings before year-end to discuss phase III pivotal trial designs.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.